Evidence map›Paper›PMID 32957990›Full record

SynthesisHealth and quality of life outcomes2020

Health related quality of life utility weights for economic evaluation through different stages of chronic kidney disease: a systematic literature review.

Jacie T Cooper, Andrew Lloyd, Juan Jose Garcia Sanchez, Elisabeth Sörstadius, Andrew Briggs, Phil McFarlane

Abstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Health and quality of life outcomes, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Health-related quality of life in chronic kidney disease patients in low- and lower-middle income countries: a systematic review and meta-analysis.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2026
    Pooled it
  2. An international compendium of health state utilities in people with HIV: a systematic review.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2025
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. "Kidney international reports · 2025
    Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jacie T CooperAvalon Health Economics, Morristown, NJ, USA.
Andrew LloydAcaster Lloyd Consulting Ltd., London, UK.ORCID https://orcid.org/0000-0002-7597-6556
Juan Jose Garcia SanchezHealth Economics and Payer Evidence Lead, Global Market Access & Pricing, AstraZeneca, Academy House, 136 Hills Road, Cambridge, CB2 8PA, UK. juanjose.garciasanchez@astrazeneca.com.ORCID https://orcid.org/0000-0001-6546-7769
Elisabeth SörstadiusPrice and Market Access Director, Global Market Access & Pricing. AstraZeneca, Mölndal, Sweden.
Andrew BriggsAvalon Health Economics, Morristown, NJ, USA.
Phil McFarlaneUniversity of Toronto, Toronto, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundA Task Force from the International Society of Pharmacoeconomics and Outcomes Research (ISPOR) provides recommendations on how to systematically identify and appraise health state utility (HSU) weights for cost-effectiveness analyses. We applied these recommendations to conduct a systematic review (SR) to identify HSU weights for different stages of chronic kidney disease (CKD), renal replacement therapy (RRT) and complications.

methodsMEDLINE® and Embase were searched for interventional and non-interventional studies reporting HSU weights for patients with CKD stages 1-5 or RRT. As per ISPOR Task Force Guidance, study quality criteria, applicability for Health Technology Assessment (HTA) and generalisability to a broad CKD population were used to grade studies as either 1 (recommended), 2 (to be considered if there are no data from grade 1 studies) or 3 (not recommended).

resultsA total of 17 grade 1 studies were included in this SR with 51 to 1767 participants, conducted in the UK, USA, Canada, China, Spain, and multiple-countries. Health related quality of life (HRQL) instruments used in the studies included were EQ-5D-3L (10 studies), SF-6D (4 studies), HUI2/HUI3 (1 study), and combinations (2 studies). Although absolute values for HSU weights varied among instruments, HSU weights decreased with CKD severity in a consistent manner across all instruments.

conclusionsThis SR identified HSU weights for a range of CKD states and showed that HRQL decreases with CKD progression. Data were available to inform cost-effectiveness analysis in CKD in a number of geographies using instruments acceptable by HTA agencies.

Indexed as

Disease ProgressionQuality of LifeAdultCost-Benefit AnalysisFemaleHumansMaleOutcome Assessment, Health CareRenal Insufficiency, ChronicSurveys and QuestionnairesCost-effectivenessCost-utilityDialysisEQ-5DHUISF-6DTransplant

Identifiers

PMID32957990
PMCPMC7507735

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.